The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma

A. Rios, Evan M Hersh, J. U. Gutterman, G. M. Mavligit, H. Schimek, J. E. McEntire, B. W. Papermaster

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A study was conducted to determine some of the potential applications of a human leukocyte culture supernatant or 'lymphokine' preparation in cancer patients. The application evaluated in this study was the use of this preparation as a skin test reagent for evaluation of the inflammatory response following intradermal injection. The preparation was derived from the supernatant of a long-term cultured lymphoblastoid cell line with migration inhibition factor (MIF) and other lymphokine activities. Dose response, histology and toxicity studies were done in 53 patients with malignant melanoma stage IIIB and IV. A dose response curve was observed for both erythema and induration at 12 and 24 hours, but not at 48 hours. An optimal intradermal dose for eliciting inflammation was determined and found to be five units. Histopathological evaluation of biopsy specimens showed a mixed cell reaction including granulocytes, eosinophils, lymphocytes and monocytes differing in lymphocyte content from the classical delayed type hypersensitivity (DTH) reaction in man. Compared with the response to recall antigens, only a weak correlation with the DTH response to the recall antigens was found. Our results support the conclusion that lymphokines may be used in the future to evaluate the ability to develop nonspecific inflammation in cancer patients, and that this inflammatory response can be obtained in a number of patients no longer capable of responding to recall antigens.

Original languageEnglish (US)
Pages (from-to)1615-1621
Number of pages7
JournalCancer
Volume44
Issue number5
StatePublished - 1979
Externally publishedYes

Fingerprint

Lymphokines
Melanoma
Leukocytes
Cell Culture Techniques
Cell Line
Skin
Delayed Hypersensitivity
Antigens
Lymphocytes
Inflammation
Intradermal Injections
Erythema
Skin Tests
Granulocytes
Eosinophils
Monocytes
Cultured Cells
Neoplasms
Histology
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rios, A., Hersh, E. M., Gutterman, J. U., Mavligit, G. M., Schimek, H., McEntire, J. E., & Papermaster, B. W. (1979). The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. Cancer, 44(5), 1615-1621.

The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. / Rios, A.; Hersh, Evan M; Gutterman, J. U.; Mavligit, G. M.; Schimek, H.; McEntire, J. E.; Papermaster, B. W.

In: Cancer, Vol. 44, No. 5, 1979, p. 1615-1621.

Research output: Contribution to journalArticle

Rios, A, Hersh, EM, Gutterman, JU, Mavligit, GM, Schimek, H, McEntire, JE & Papermaster, BW 1979, 'The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma', Cancer, vol. 44, no. 5, pp. 1615-1621.
Rios A, Hersh EM, Gutterman JU, Mavligit GM, Schimek H, McEntire JE et al. The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. Cancer. 1979;44(5):1615-1621.
Rios, A. ; Hersh, Evan M ; Gutterman, J. U. ; Mavligit, G. M. ; Schimek, H. ; McEntire, J. E. ; Papermaster, B. W. / The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma. In: Cancer. 1979 ; Vol. 44, No. 5. pp. 1615-1621.
@article{fe37cc5d24c647e9ad7a4337b7078cd9,
title = "The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma",
abstract = "A study was conducted to determine some of the potential applications of a human leukocyte culture supernatant or 'lymphokine' preparation in cancer patients. The application evaluated in this study was the use of this preparation as a skin test reagent for evaluation of the inflammatory response following intradermal injection. The preparation was derived from the supernatant of a long-term cultured lymphoblastoid cell line with migration inhibition factor (MIF) and other lymphokine activities. Dose response, histology and toxicity studies were done in 53 patients with malignant melanoma stage IIIB and IV. A dose response curve was observed for both erythema and induration at 12 and 24 hours, but not at 48 hours. An optimal intradermal dose for eliciting inflammation was determined and found to be five units. Histopathological evaluation of biopsy specimens showed a mixed cell reaction including granulocytes, eosinophils, lymphocytes and monocytes differing in lymphocyte content from the classical delayed type hypersensitivity (DTH) reaction in man. Compared with the response to recall antigens, only a weak correlation with the DTH response to the recall antigens was found. Our results support the conclusion that lymphokines may be used in the future to evaluate the ability to develop nonspecific inflammation in cancer patients, and that this inflammatory response can be obtained in a number of patients no longer capable of responding to recall antigens.",
author = "A. Rios and Hersh, {Evan M} and Gutterman, {J. U.} and Mavligit, {G. M.} and H. Schimek and McEntire, {J. E.} and Papermaster, {B. W.}",
year = "1979",
language = "English (US)",
volume = "44",
pages = "1615--1621",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - The use of a leukocyte cell line culture supernatant for skin reaction testing in malignant melanoma

AU - Rios, A.

AU - Hersh, Evan M

AU - Gutterman, J. U.

AU - Mavligit, G. M.

AU - Schimek, H.

AU - McEntire, J. E.

AU - Papermaster, B. W.

PY - 1979

Y1 - 1979

N2 - A study was conducted to determine some of the potential applications of a human leukocyte culture supernatant or 'lymphokine' preparation in cancer patients. The application evaluated in this study was the use of this preparation as a skin test reagent for evaluation of the inflammatory response following intradermal injection. The preparation was derived from the supernatant of a long-term cultured lymphoblastoid cell line with migration inhibition factor (MIF) and other lymphokine activities. Dose response, histology and toxicity studies were done in 53 patients with malignant melanoma stage IIIB and IV. A dose response curve was observed for both erythema and induration at 12 and 24 hours, but not at 48 hours. An optimal intradermal dose for eliciting inflammation was determined and found to be five units. Histopathological evaluation of biopsy specimens showed a mixed cell reaction including granulocytes, eosinophils, lymphocytes and monocytes differing in lymphocyte content from the classical delayed type hypersensitivity (DTH) reaction in man. Compared with the response to recall antigens, only a weak correlation with the DTH response to the recall antigens was found. Our results support the conclusion that lymphokines may be used in the future to evaluate the ability to develop nonspecific inflammation in cancer patients, and that this inflammatory response can be obtained in a number of patients no longer capable of responding to recall antigens.

AB - A study was conducted to determine some of the potential applications of a human leukocyte culture supernatant or 'lymphokine' preparation in cancer patients. The application evaluated in this study was the use of this preparation as a skin test reagent for evaluation of the inflammatory response following intradermal injection. The preparation was derived from the supernatant of a long-term cultured lymphoblastoid cell line with migration inhibition factor (MIF) and other lymphokine activities. Dose response, histology and toxicity studies were done in 53 patients with malignant melanoma stage IIIB and IV. A dose response curve was observed for both erythema and induration at 12 and 24 hours, but not at 48 hours. An optimal intradermal dose for eliciting inflammation was determined and found to be five units. Histopathological evaluation of biopsy specimens showed a mixed cell reaction including granulocytes, eosinophils, lymphocytes and monocytes differing in lymphocyte content from the classical delayed type hypersensitivity (DTH) reaction in man. Compared with the response to recall antigens, only a weak correlation with the DTH response to the recall antigens was found. Our results support the conclusion that lymphokines may be used in the future to evaluate the ability to develop nonspecific inflammation in cancer patients, and that this inflammatory response can be obtained in a number of patients no longer capable of responding to recall antigens.

UR - http://www.scopus.com/inward/record.url?scp=0018567108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018567108&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1615

EP - 1621

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -